Ananda Lewis chose 'natural' cancer care over conventional treatment. Many others do too -- and it's risky
After revealing in 2020 that she had been battling breast cancer for more than two years, Lewis announced she was foregoing conventional treatment in favor of holistic methods such as juicing, herbal remedies and detox regimens.
Lewis' cancer had already reached an advanced stage by the time it was detected -- delayed in part by her long-standing fear of mammograms and concerns about radiation exposure.
MORE: Former MTV VJ and talk show host Ananda Lewis dies at 52
Like Lewis, some cancer patients are questioning traditional cancer care and turning to alternative therapies instead. Famously, Steve Jobs, the co-founder of Apple Inc., delayed surgery after being diagnosed with pancreatic cancer in favor of vegan diet, cleanses and herbal remedies.
Fewer than one percent of cancer patients refuse all treatment, according to a May 2022 study. However, another study found that upwards of 19% decline at least some of the recommended treatment, including chemotherapy and radiation.
Foregoing traditional treatments can have dire consequences.
Patients with breast or colorectal cancer who chose alternative treatments were nearly five times more likely to die, and those with non-metastatic lung cancer had more than double the risk, according to a 2017 study from Yale School of Medicine.
"What's at stake here is life and death. We know that particularly early detection saves lives," Dr. Elizabeth Comen, a breast oncologist at NYU Langone Hospital, told ABC News.
Comen said doctors need to explore why some patients distrust the system even though modern medicine has greatly improved cancer outcomes.
Many patients who decline conventional treatments do so due to fear of side effects, distrust of the medical system or a desire for control, Comen said. They often choose natural remedies believing these are safer or better for their health.
MORE: Women diagnosed with breast cancer in their 20s, 30s, 40s describe being robbed of their femininity
It may be an enticing idea that the body can just heal itself, Comen conceded.
The wellness industry and social media often glamorize "natural healing," pushing unproven treatments as safer than standard care, according to Comen. In the face of a scary diagnosis and growing mistrust, some patients see alternative therapies as more hopeful, she said.
"I've seen patients mortgage their home, drain their entire finances for presumably magic bullets that they've seen online." Comen said.
Complementary care can be helpful, but only when combined with standard treatment, Comen cautioned.
Practices like acupuncture, mindfulness meditation and yoga can help reduce treatment-related side effects such as pain, fatigue and anxiety, Comen said. She added there is robust evidence that diet and exercise can improve outcomes and quality of life.
A 2022 study found physical activity -- in addition to rather than in lieu of treatment -- decreases the severity of side effects of cancer treatment, reduces fatigue, has a positive impact on mental health and improves quality of life.
Comen emphasized that early, evidence-based treatment is crucial to improve the odds of survival, especially for aggressive cancers. Returning to conventional care after trying alternative methods risks progression of the disease past the point where doctors can contain it, she added.
"I have countless heart-breaking stories of patients not trusting a medical system, being sold a false bill of goods by someone that is not medically trained, and they often come back when they have been abandoned," she said. "They come back to me when honestly it is too late to be able to provide curative intent. Those stories haunt me."
Dr. Lemuel Hackshaw, MD, is an emergency medicine chief resident at Mayo Clinic in Rochester, Minnesota, and a member of the ABC News Medical Unit.
Ananda Lewis chose 'natural' cancer care over conventional treatment. Many others do too -- and it's risky originally appeared on abcnews.go.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Back-to-School Ready? MySmile's 15% Off Sale is Here!
MySmile launches its Back-to-School sale, offering 15% off all oral care products until August 22, helping students head back to school with healthy and confident smiles. LOS ANGELES, Aug. 20, 2025 /PRNewswire/ -- As backpacks get packed and classrooms come alive again, MySmile, a trusted leader in innovative and affordable oral care solutions, is excited to announce its Back-to-School Sale, running now through August 22. Families and students can take advantage of 15% off every product on MySmile's website —from advanced sonic toothbrushes and portable water flossers to natural ingredient-based toothpaste—making it easier than ever to head into the school year with healthy, confident smiles. Why Oral Care Matters This Back-to-School Season While back-to-school shopping often centers on supplies and outfits, oral care is just as essential. According to dental experts, oral health plays a direct role in self-confidence, classroom focus, and long-term well-being. Poor oral hygiene can lead to discomfort, missed school days, and even lower self-esteem—making the right oral care products as important as a new backpack or laptop. "Back-to-school isn't just about new pencils and textbooks; it's about setting up students for success in every area of life," said Bobby Jacob, Founder of MySmile. "A confident smile can boost a student's self-esteem and help them feel ready to take on the year ahead. Our Back-to-School Sale is designed to give families access to professional-quality oral care at affordable prices." Top Back-to-School Oral Care Tips from MySmile To keep smiles healthy and bright throughout the school year, MySmile recommends the following simple yet effective oral care habits: Make Brushing Count – Encourage students to brush for at least two minutes, twice daily. The MySmile Sonic Toothbrush uses advanced sonic technology to remove plaque more effectively than manual brushing. Don't Skip the Floss – A cordless ( water flosser makes flossing easy, quick, and even fun. Portable designs are perfect for college students, athletes, and anyone with braces. Choose Gentle, Natural Ingredients – Toothpaste that's free of harsh chemicals but packed with natural ingredients can protect enamel, freshen breath, and support long-term oral health. The MySmile Natural Toothpaste is specially formulated for safe everyday use. Consistency Is Key – Creating daily oral care routines helps students build healthy habits that last well beyond the school year. Must-Have Oral Care Products for Students MySmile Cordless Water Flosser – Compact, portable, and powerful, it's ideal for dorm rooms, backpacks, and athletes on the go. MySmile Sonic Toothbrush – Affordable yet professional, ensuring a deep clean for healthier gums and brighter smiles. MySmile Natural Toothpaste – Made with gentle, effective ingredients that support oral health without synthetic additives. These products are not only highly rated by customers worldwide but are also designed to be affordable, student-friendly, and effective. Back-to-School Sale Details The Back-to-School Sale is live now on . Customers can enjoy 15% off every product sitewide until August 22 . Whether shopping for a high schooler with braces, a college student moving into a dorm, or simply refreshing the family's oral care kit, this sale provides the perfect opportunity to stock up on essentials. Shop the Sale Today The countdown to a brighter, healthier school year is on. Don't miss your chance to save 15% on all MySmile products —now through August 22. Shop Now at Media Contact: For Media, contact Winnie, Digital Marketing Manager at winnie@ MySmile is a leading brand dedicated to revolutionizing oral care with innovative products that deliver professional results from the comfort of your home. Specializing in whitening, gum health, and overall dental wellness, MySmile offers a variety of high-quality oral care solutions, including whitening kits, portable mouthwash, water flossers, and toothbrushes. Available online and at top retailers like Amazon,Target, Macy's, and Kohl's, MySmile is committed to making it easier for people to achieve their dream smile. With a focus on simplicity, effectiveness, and customer satisfaction. View original content to download multimedia: SOURCE MySmile Oral Care Inc. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a minute ago
- Yahoo
Doctor's Best Launches Women's Multi-Vitamin
New Formula Features 21 Essential Nutrients, Made for Women, from Women TUSTIN, Calif., Aug. 20, 2025 /PRNewswire/ -- Doctor's Best Inc., a leading nutritional supplement company, has announced the launch of its latest product, a Women's Multi-Vitamin, for women of all ages, featuring essential vitamins and minerals to support everyday wellness.* This new formula provides 21 essential nutrients, including full-spectrum B vitamins. Among these are active Folate (Vitamin B9) in the form of L-5-Methyltetrahydrofolate and Methylcobalamin (Vitamin B12). These active forms can provide prenatal support for individuals who may not efficiently process Folic Acid due to their genetic makeup.1 "It can be challenging to meet daily nutritional needs solely through diet for various reasons, including access to nutrient-rich food, time constraints, and individual food preferences," said Gale Bensussen, CEO of Doctor's Best. "It's vital that women have the support they need through a high-quality multi-vitamin throughout various life stages, especially if they are considering pregnancy in the near future." The Women's Multi-Vitamin is part of the Doctor's Best Women's Collection, a line of science-backed supplements designed to support women's specific health needs at key life stages. Recognizing the need for proven formulas specifically designed for women, the company's team of experts studied the science and gathered customer feedback to create supplements they would use personally or recommend to their loved ones. In addition to launching the new Women's Multi-Vitamin, Doctor's Best is committed to reducing waste. The brand is phasing out plastic neckbands and sleeves on its products, which will save about 40,000 lbs. of plastic each year. They have also decreased the amount of cardboard used for shipping, resulting in nearly 203,000 pounds of cardboard savings annually. About Doctor's Best Women's Multi-Vitamin - This comprehensive women's multivitamin is formulated to support daily energy.* Packed with essential vitamins like A, C, D and E for immune support and healthy skin, alongside vital minerals including calcium for bone health and magnesium for muscle function.* This formula also includes full-spectrum B vitamins, boosting energy and metabolism to help women stay energized and vibrant every day.* • Boosts your day with 21 essential nutrients for balanced wellness*• Supports immunity, energy, bone and muscle function* Doctor's Best Women's Muli-Vitamin is non-GMO and gluten-free. It is currently available on and iHerb. For more information on Doctor's Best, please visit and follow @DoctorsBestVitamins on Instagram, TikTok and Facebook. About Doctor's Best®Doctor's Best is a leading, science-based nutritional supplement company driven by a mission to empower families to lead a healthy lifestyle and thrive outside the doctor's office. Founded by a physician more than 30 years ago, Doctor's Best offers more than 200 products. It has built a stellar reputation in the nutritional supplement industry for utilizing branded ingredients, demonstrating proven potency, safety, and clinically studied efficacy. All Doctor's Best products are manufactured and rigorously tested exclusively at Current Good Manufacturing Practice (cGMP) certified facilities in the United States. Based in Tustin, California, Doctor's Best products are found on retail sites such as Amazon and iHerb, as well as major retailers and specialty chains, including and Sprouts. For more information, please visit Media Contact: Marissa Sanchez Buntz, marissa@ * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. 1 J Perinat Med. 2013 Sep 1;41(5):469-83. doi: 10.1515/jpm-2012-0256. View original content to download multimedia: SOURCE Doctor's Best
Yahoo
a minute ago
- Yahoo
iSpecimen's $6M Valuation Doesn't Reflect the Business-Let Alone the $200M Treasury (NASDAQ: ISPC)
WOBURN, MA / / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025) The digital treasury announcement deserved headlines. It's rare for any microcap, especially in life sciences, to unveil a capital strategy of that scale. But the attention came with a surprising market reaction. Following the news, ISPC shares moved lower. That drop wasn't tied to any breakdown in the business. It was likely due to timing. The news hit after-hours, when retail investors had little access and institutions hadn't yet responded. What the market saw was the number. What it didn't see was the system behind it. Solving the Bottleneck in Life Sciences iSpecimen is not a clinical-stage biotech, nor is it speculative software. It operates a fully functional digital marketplace for human biospecimens-vital inputs for both preclinical and clinical research. The platform allows researchers to efficiently source high-quality, well-characterized specimens with full traceability and regulatory compliance. Blood, plasma, tissue, and genomically sequenced material are the raw materials of discovery, yet sourcing them has long been a fragmented, manual, and inefficient process. iSpecimen fixes that. Its proprietary, cloud-based platform lets researchers search, filter, and request exactly what they need based on disease state, demographic, clinical history, or processing requirements. On the other end, hospitals and labs can monetize excess inventory. iSpecimen handles compliance, logistics, and invoicing. The result is a streamlined transaction that unlocks value for both sides. This isn't a roadmap or beta test. The platform is live, and it's producing revenue. In 2024, the company posted $9.29 million in revenue. That number didn't come from grants or one-time licensing. It came from platform activity, repeated use, and institutional adoption. The Treasury is Not a Gimmick - It's a Strategic Asset The $200 million digital treasury that sparked attention isn't accounted for as cash on the balance sheet. But that doesn't mean it lacks financial weight. It is a capital preservation and liquidity strategy built to support long-term operations. Built on Solana, it features insured custody, cold storage, and a risk-managed structure that removes reliance on traditional capital markets. This isn't a distraction. It's financial insulation. It allows iSpecimen to grow without falling into the trap of repeated, dilutive financing. That kind of flexibility, especially for a microcap, is rare. But while the market focused on that headline, it missed the infrastructure behind it. iSpecimen's core business is still the real story. Expanding Reach Across Critical Therapeutic Areas Behind the scenes, the company is scaling its footprint across several high-value segments of medicine. In cancer research, it's now working with U.S.-based oncology centers and a genomic sequencing partner to deliver hard-to-source biospecimens for precision studies. In women's health, iSpecimen has access to over 600,000 patients through multi-state partnerships, unlocking samples across reproductive, hormone, and breast health. And in early 2025, the company proactively secured sourcing for human metapneumovirus (hMPV), anticipating potential waves of global research interest. Each of these initiatives adds operational depth to a platform that was already delivering. None of it would matter if the core system didn't work. But it does, and the results are increasingly visible. When the Market Doesn't Know Where to Look The mispricing here may stem from the fact that iSpecimen doesn't fit cleanly into a familiar category. It's not chasing regulatory approval, so it doesn't trade on FDA calendars. It's not a SaaS company, though its platform behaves like one. Instead, it sits between logistics, life sciences, and digital infrastructure - and that ambiguity often delays recognition. But that's also where value hides. iSpecimen runs an asset-light, transaction-based model. It doesn't need to build labs or develop its own trial pipeline. It monetizes what already exists by organizing and standardizing the connections between researchers and providers. That model is scalable across disease areas, institutions, and even global geographies. This Isn't a Bet. It's a Repricing in Progress The treasury may have been the headline, but it isn't the whole story. It's simply a structural advantage layered onto a business that is already performing. The marketplace, the revenue, the partnerships, and the platform all existed before the $200 million plan was announced. Thus, ISPC isn't a company hoping for validation. It's a company that already has it - just not from the market yet. At $1.11, the share price reflects none of that. But that doesn't mean the value isn't there. It just means the recognition hasn't arrived yet. When it does, the most temporary number in this entire story might be the one investors are staring at right now. *Reprinted with permission from Hawk Point Media Group, LLC. About iSpecimen iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact:Investor Contactsinfo@ For this content only: info@ Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five thousand dollars to create this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated beyond the channels used by Hawk Point Media, LLC. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in iSpecimen Inc. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. SOURCE: iSpecimen, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
